652 related articles for article (PubMed ID: 17158759)
1. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
2. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
[TBL] [Abstract][Full Text] [Related]
3. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel ER-alpha target genes in breast cancer cells: gene- and cell-selective co-regulator recruitment at target promoters determines the response to 17beta-estradiol and tamoxifen.
Romano A; Adriaens M; Kuenen S; Delvoux B; Dunselman G; Evelo C; Groothuis P
Mol Cell Endocrinol; 2010 Jan; 314(1):90-100. PubMed ID: 19698761
[TBL] [Abstract][Full Text] [Related]
6. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
8. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer.
Myers E; Fleming FJ; Crotty TB; Kelly G; McDermott EW; O'higgins NJ; Hill AD; Young LS
Br J Cancer; 2004 Nov; 91(9):1687-93. PubMed ID: 15477868
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
[TBL] [Abstract][Full Text] [Related]
10. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
[TBL] [Abstract][Full Text] [Related]
11. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
12. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Buggy Y; Young LS
Clin Cancer Res; 2005 Mar; 11(6):2111-22. PubMed ID: 15788656
[TBL] [Abstract][Full Text] [Related]
13. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
[TBL] [Abstract][Full Text] [Related]
14. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
Chong K; Subramanian A; Sharma A; Mokbel K
Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
[TBL] [Abstract][Full Text] [Related]
15. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
17. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
[TBL] [Abstract][Full Text] [Related]
18. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
19. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
20. The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer.
Spears M; Bartlett J
Expert Opin Ther Targets; 2009 Jun; 13(6):665-74. PubMed ID: 19456271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
